Related Experiment Video

Updated: Jan 7, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.1K

YK-4-279 Induces Osteosarcoma Cell Cycle Arrest, DNA Damage Response, and Apoptosis by Regulating the MAPK Cascade

Weifeng Wang1,2,3, Yuli Zhang4,5, Xiuqin Jia6

  • 1Department of Orthopedic Surgery, Beijing Jishuitan Hospital Liaocheng Hospital, Liaocheng, Shandong, People's Republic of China.

Drug Design, Development and Therapy
|January 2, 2026
PubMed
Abstract

Insights

YK-4-279 effectively inhibits osteosarcoma (OS) cell growth by inducing DNA damage and apoptosis. This anticancer agent activates the MAPK pathway, showing significant therapeutic potential for treating this aggressive bone cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Osteosarcoma (OS) is an aggressive bone cancer with limited treatment options, particularly for adolescents.
  • YK-4-279 is an emerging anticancer agent with demonstrated efficacy against various tumors.
  • Understanding YK-4-279's mechanism of action in OS is crucial for its clinical application.

Purpose of the Study:

  • To investigate the effects of YK-4-279 on osteosarcoma cell behavior in vitro.
  • To elucidate the role of the MAPK signaling pathway in YK-4-279's anticancer activity.
  • To evaluate YK-4-279 as a potential therapeutic agent for osteosarcoma.

Main Methods:

  • In vitro studies using osteosarcoma cell models.
  • Assessment of cell viability, proliferation, apoptosis, cell cycle, and DNA damage.
  • Analysis of MAPK pathway activation (ERK1/2, JNK, P38) and combined treatment with a P38 inhibitor.

Main Results:

  • YK-4-279 significantly reduced OS cell viability and proliferation.
  • The agent induced G2/M phase arrest, increased apoptosis, and caused DNA damage.
  • YK-4-279 activated the MAPK pathway; P38 inhibition partially reversed the effects, confirming pathway involvement.

Conclusions:

  • YK-4-279 demonstrates potent anticancer effects against osteosarcoma cells.
  • The drug functions by inducing DNA damage, cell cycle arrest, and apoptosis, mediated by MAPK pathway activation.
  • YK-4-279 holds considerable therapeutic promise for osteosarcoma treatment.
Keywords:
DNA damageMAPK signaling pathwayYK-4-279apoptosiscell cycleosteosarcoma

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.4K
Preparation of Cell-lines for Conditional Knockdown of Gene Expression and Measurement of the Knockdown Effects on E4orf4-Induced Cell Death13:54

Preparation of Cell-lines for Conditional Knockdown of Gene Expression and Measurement of the Knockdown Effects on E4orf4-Induced Cell Death

Published on: October 21, 2012

11.3K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.0K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K